Celandine Poppy (Stylophorum diphyllum)

Celandine poppy (Stylophorum diphyllum) is a North American wildflower containing benzylisoquinoline alkaloids including berberine and sanguinarine. Current research focuses only on phytochemical identification and genetic analysis, with no established therapeutic applications or clinical studies in humans.

Origin & History

Stylophorum diphyllum, known as Celandine Poppy, is a perennial herbaceous plant native to eastern North America belonging to the Papaveraceae family. As a benzylisoquinoline alkaloid (BIA)-producing species, it synthesizes protoberberine and aporphine alkaloids similar to related poppy family genera. Current research focuses on whole-plant transcriptomes and metabolomes rather than commercial extracts or standardized preparations.

Historical & Cultural Context

No historical or traditional medicinal uses are documented for Stylophorum diphyllum within global medical systems. The plant appears primarily as a wild ornamental or ecological study subject in North American contexts, without references to ethnobotanical applications.

Health Benefits

• No clinically validated health benefits - all research is limited to phytochemical and genetic studies
• Potential alkaloid biosynthesis pathways identified through transcriptome analysis - but no therapeutic applications studied
• May theoretically share properties with related Papaveraceae species - but no specific evidence exists
• Environmental phenology studies conducted - but provide no therapeutic insights
• Genetic expression patterns documented - but functional validation in humans is completely lacking

How It Works

Celandine poppy produces benzylisoquinoline alkaloids through specialized biosynthesis pathways, including berberine and potentially sanguinarine. These alkaloids theoretically could interact with microbial cell walls and inflammatory pathways similar to other Papaveraceae species. However, specific receptor interactions and enzymatic effects remain unstudied for this particular species.

Scientific Research

No human clinical trials, RCTs, or meta-analyses exist for Stylophorum diphyllum in PubMed-indexed sources. Available research is entirely preclinical, focusing on genetic expression, transcriptome analysis, and alkaloid pathway candidates, with no data on efficacy or safety in humans. Phenological studies examine environmental impacts on flowering but offer no therapeutic evidence.

Clinical Summary

No clinical trials have been conducted on Stylophorum diphyllum in humans or animals. Research is limited to transcriptome analysis identifying alkaloid biosynthesis genes and phytochemical profiling studies. Current evidence consists entirely of laboratory-based genetic and chemical characterization studies. No therapeutic efficacy, safety, or dosage data exists from controlled studies.

Nutritional Profile

Celandine Poppy (Stylophorum diphyllum) is not a food ingredient and has no established nutritional profile as a dietary source. It is not consumed for macronutrients, micronutrients, fiber, or protein. Phytochemical analysis confirms the presence of isoquinoline alkaloids as the primary bioactive compounds, including chelidonine, sanguinarine, chelerythrine, and berberine — compounds also documented in related Papaveraceae family members. Transcriptome studies have mapped alkaloid biosynthesis pathways, confirming enzymatic production of benzylisoquinoline alkaloids (BIAs) within plant tissues, particularly concentrated in the latex/sap. Sanguinarine concentrations in related species typically range from 0.1–1.5% dry weight in aerial parts. Chelidonine has been identified as a dominant alkaloid in genus-related plants at comparable concentrations. These alkaloids exhibit very low oral bioavailability due to first-pass metabolism and are classified as cytotoxic at elevated doses. No vitamins, dietary minerals, or macronutrient data are applicable or have been studied. The plant's latex contains proteolytic enzymes similar to those in Chelidonium majus, though no quantification exists for S. diphyllum specifically. All alkaloid content data is inferred from phylogenetic and transcriptomic proximity to Chelidonium majus rather than direct chemical quantification of this species.

Preparation & Dosage

No clinically studied dosage ranges exist for any form of Stylophorum diphyllum, as no human trials have been conducted. Standardization protocols are not applicable due to the complete absence of therapeutic studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic combinations studied, Related species: Chelidonium majus, Other Papaveraceae alkaloid producers

Safety & Interactions

Safety profile is completely unknown due to absence of toxicological studies. As a member of the Papaveraceae family containing alkaloids, it may pose risks similar to related species including potential hepatotoxicity and drug interactions. Pregnancy and breastfeeding safety is unknown and should be avoided. May theoretically interact with medications metabolized by cytochrome P450 enzymes due to alkaloid content.